Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far

Manisha Saini; Minakshi Rana; Karun BhattiRina DasDinesh MehtaRam Chidurala

首页> 外文期刊>Current drug research reviews. >Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far

【24h】

Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far

机译：Remdesivir和Favipiravir的临床疗效COVID-19患者的治疗:场景远

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The novel SARS-CoV-2 is a new disease that has caused severe destruction to human lives across the globe, including infection, mortality and financial crises, for which, scientific researchers have been directed towards the development of treatment and controlling measures against coronavirus. Currently, there has been no approved drug for the treatment of the disease, but several antiviral drugs have shown therapeutic effects from which, remdesivir and favipiravir are two such drugs. These drugs have shown some therapeutic potential in the treatment of COVID-19 by inhibiting viral enzyme RNA-dependent RNA polymerase. The purpose of this systematic review is to provide an overview of the effectiveness of these two drugs based on the clinical trials reported in current published data.

机译：这部小说SARS-CoV-2是一种新的疾病对人类生活造成了严重破坏全球范围内,包括感染,死亡率和金融危机,科学研究人员已经指向治疗和控制措施的发展对冠状病毒。通过药物治疗疾病,但一些抗病毒药物显示治疗效果,remdesivir和favipiravir是两个这样的药物。显示一些治疗潜在的治疗COVID-19通过抑制病毒的酶依赖RNA的RNA聚合酶。系统评价是提供的概述这两种药物的基础上的有效性在当前发表的临床试验报告数据。

著录项

来源
《Current drug research reviews.》 |2022年第1期|11-19|共9页
作者
Manisha Saini; Minakshi Rana; Karun BhattiRina DasDinesh MehtaRam Chidurala;
展开▼
作者单位

M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be) University, Mullana, Ambala, HR;

Department of Medicine, M.M. Institute of Medical Sciences and Research, Maharishi Markandeshwar;

Department of Medicine, Medstar Southern Maryland Hospital,7503, Surratts Rd, Clinton, Maryland;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类
关键词

相似文献

外文文献
中文文献

1. Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study [J] . Tominaga A., Wada K., Kato Y., Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA . 2021,第4期

机译：Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study
2. OVERVIEW OF FAVIPIRAVIR AND REMDESIVIR TREATMENT FOR COVID-19 [J] . E. Eroglu, C. Toprak International Journal of Pharmaceutical Sciences and Research . 2021,第4期

机译：Covid-19的Favipiravir和Remdesivir治疗概述
3. Two Cases of Severe COVID-19 Pneumonia Effectively Treated with Extracorporeal Membrane Oxygenation in Addition to Favipiravir and Corticosteroid [O] . Masahiro Shinoda, Kenichi Kamachi, Shinichiro Ota, 2021

机译：除了FaviPiravir和皮质类固醇之外两种严重的Covid-19肺炎的严重Covid-19肺炎
4. Clinical Implications of High MET Gene Dosage in Non-Small Cell Lung Cancer Patients without Previous Tyrosine Kinase Inhibitor Treatment [O] . Chen, Y.T., Chang, J.W.C., Liu, H.P., 2014

机译：Clinical Implications of High mET Gene Dosage in Non-small Cell Lung Cancer patients without previous Tyrosine Kinase Inhibitor Treatment

Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far

摘要

著录项

相似文献

相关主题

期刊订阅